Matthew Rovorgian's questions to FOXO TECHNOLOGIES (FOXO) leadership • Q2 2023
Question
Matthew Rovorgian from Maxim Group inquired about FOXO's commercialization strategy for the upcoming three to four quarters and what investors should expect.
Answer
Executive Tyler Danielson explained that FOXO is currently doubling down on R&D to ensure proper market fit before full commercialization. While not disclosing specific future products due to their proprietary nature, he highlighted significant opportunities in large health and wellness markets. Danielson emphasized that continued R&D in epigenetics is crucial for discovering new markers and is the company's primary focus.